Search

everythinglearnresearchcommunity

for

Search:↓

Some plant-based products might treat hair loss with fewer side effects than current medications.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.

5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.

5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

Finasteride, when given in high oral doses to pregnant monkeys, caused genital abnormalities in male fetuses, but not in female fetuses or those exposed to intravenous finasteride.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.